{
  "id": 13956735,
  "title": "Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.",
  "url": "https://urgent.news/2026/10/12/oppenheimer-thinks-viking-therapeutics-stock-can-soar-to-120-heres-13956735",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T11:42:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/oppenheimer-thinks-viking-therapeutics-stock-can-soar-120-heres-math-behind-ultra-bullish"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsAnalyst opinions and sales projections for weight loss and type 2 diabetes drug VK2735 vary widely, reflecting both promise and uncertainty.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.",
        "url": "https://urgent.news/2026/10/12/oppenheimer-thinks-viking-therapeutics-stock-can-soar-to-120-heres",
        "published": "2026-10-12T11:22:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}